Competitive intelligence on 
 small-molecule drugs and 
 the 90,000 global patents 
 covering them 

Start your free trial now

DrugPatentWatch Ultimate Plan Preview

Profile for Tradename: EMEND

« Back to Dashboard

Emend is a drug marketed by Merck and Merck And Co Inc and is included in two NDAs. It is available from three suppliers. There are seven patents protecting this drug and three Paragraph IV challenges.

The generic ingredient in EMEND is fosaprepitant dimeglumine. There are three drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the fosaprepitant dimeglumine profile page.

Summary for Tradename: EMEND

Patents:7
Applicants:2
NDAs:2
Suppliers: see list3

Clinical Trials for: EMEND

Efficacy of Aprepitant (Emend®) in Children
Status: Recruiting Condition: Nausea; Vomiting; Childhood Cancer

A Study of MK-0869 (Aprepitant) and MK-0517 (Fosaprepitant) in Pediatric Participants Receiving Chemotherapy (MK-0869-134)
Status: Terminated Condition: Chemotherapy-Induced Nausea and Vomiting

Aprepitant's Effect on Drug Metabolism in Multi-Day Combination (CHOP/R-CHOP) Chemotherapy Regimen in Lymphoma Patients
Status: Completed Condition: Lymphoma

Re-examination Study of EMEND (Aprepitant) (MK-0869-184)
Status: Completed Condition: Chemotherapy-induced Nausea and Vomiting

Pharmacokinetic (PK) Characteristics and Anti-Inflammatory Effects of the NK-1R Antagonist, Aprepitant, In HIV-Infected Subjects With Undetectable Viral Load Receiving Atazanavir/Ritonavir Or Darunavir/Ritonavir-Containing Antiretroviral Therapy
Status: Recruiting Condition: HIV Infection

Study of the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Fosaprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Children (MK-0517-029)
Status: Recruiting Condition: Chemotherapy-induced Nausea and Vomiting

A Study of Aprepitant (MK-0869) in Pediatric Participants Undergoing Surgery (MK-0869-148)
Status: Completed Condition: Postoperative Nausea and Vomiting

Topical Aprepitant in Prurigo Patients
Status: Completed Condition: Pruritus

Fosaprepitant for Nausea and Vomiting During High-dose Interleukin-2 (HD IL-2) for Metastatic Melanoma and Renal Cell Carcinoma
Status: Recruiting Condition: Chemotherapy-induced Nausea and Vomiting

Aprepitant Effects on Oxycodone Response
Status: Completed Condition: Narcotic Abuse

Courtesy of ClinicalTrials.org
See more clinical trials for this drug
Glossary
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Merck And Co Inc
EMEND
fosaprepitant dimeglumine
POWDER;INTRAVENOUS022023Nov 12, 2010RXYes<disabled><disabled>
Merck And Co Inc
EMEND
fosaprepitant dimeglumine
POWDER;INTRAVENOUS022023Jan 25, 2008DISCNNo5,538,982<disabled><disabled>
Merck And Co Inc
EMEND
fosaprepitant dimeglumine
POWDER;INTRAVENOUS022023Nov 12, 2010RXYes5,716,942<disabled><disabled>
Merck
EMEND
aprepitant
CAPSULE;ORAL021549Mar 26, 2003RXYes8,258,132<disabled>Y<disabled>
Merck
EMEND
aprepitant
CAPSULE;ORAL021549Mar 26, 2003RXNo8,258,132<disabled>Y<disabled>
This preview shows a limited data set
Subscribe for full access, or try a free trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for: EMEND

Drugname Dosage Strength RLD Submissiondate
fosaprepitant dimeglumineInjection150 mg/vialEmend1/25/2012
fosaprepitant dimeglumineInjection115 mg/vialEmend1/25/2012
aprepitantCapsule40 mg, 80 mg and 125 mgEmend11/3/2008
« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000   2001   2002   2003   2004   2005   2006   2007   2008   2009   2010   2011   2012   2013  

For more information try a free trial or see the plan comparison

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Connect with Social Media:

Follow DrugPatentWatch on Twitter Connect with DrugPatentWatch on Linkedin Drug Patents on LinkedIn

Copyright © 2002-2014 thinkBiotech LLC. ISSN: 2162-2639

Other thinkBiotech sites: PatentStatBiotechBlogJournal of Commercial Biotechnology

`abc